Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
August 11, 2020 04:06 ET
|
Kymab Group Ltd
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis KY1005 met both primary end points demonstrating: A clinically meaningful improvement in disease activity...